

Advances in blood cancer patient monitoring: Why MRD should be part of the conversation

Please join us for educational programs and interactive discussions with renowned physicians to discuss the utility of minimal residual disease (MRD) assessment in blood cancers.

Hosted by **Adaptive** biotechnologies®

A series of live, one-hour webinar events that include participant polling and Q&A sessions with the experts.

Multiple Myeloma



Ola Landgren, MD, PhD
*Chief Attending Physician of the Myeloma Service, Memorial Sloan-Kettering Cancer Center
Professor of Medicine at Weill Cornell Medical College*

Dr. Landgren is Chief Attending Physician of the Myeloma Service at Memorial Sloan-Kettering Cancer Center and Professor of Medicine at Weill Cornell Medical College. Over the past decade, he has designed and conducted a series of studies to define biological mechanisms of transformation from myeloma precursor disease (MGUS and smoldering myeloma) to multiple myeloma. He has designed several clinical studies designed to seek rapid and deep responses. Beyond clinical criteria for complete remission, he has developed strategies to define minimal residual disease (MRD) detection post-therapy in multiple myeloma and high-risk smoldering myeloma patients, using cell-, molecular-, and imaging-based methods.

Monday, May 11th
6pm–7pm EST

RSVP NOW



Parameswaran Hari, MD, MRCP, MS
*Armand J. Quick/William F. Stapp Professor of Hematology, Medical College of Wisconsin
Chief in the Division of Hematology and Oncology in the Department of Medicine*

Parameswaran Hari, MD, MRCP, MS, is the Armand J. Quick/William F. Stapp Professor of Hematology at Medical College of Wisconsin. Dr. Hari serves as Chief in the Division of Hematology and Oncology in the Department of Medicine. After medical school in India, he completed training in Internal Medicine and Hematology in the United Kingdom and then in Medical Oncology and Transplantation at the Medical College of Wisconsin. His primary clinical interests are in cellular therapies and plasma cell disorders - multiple Myeloma, Amyloidosis and other monoclonal gammopathies. Dr. Hari is also Scientific Director of the plasma cell disorders working committee of the Center for International Blood and Marrow Transplant Research (CIBMTR).

Wednesday, May 13th
6pm–7pm CST

RSVP NOW

Additional programs available on MRD in acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL). Programs on MRD in chronic myeloid leukemia (CML) and acute myeloid leukemia (AML) forthcoming.